Anzeige
Mehr »
Login
Sonntag, 14.08.2022 Börsentäglich über 12.000 News von 670 internationalen Medien
Aktie mit deutlich anziehendem Volumen und Kann die LPT-Plattform die Medizin in vielen Bereichen revolutionieren?Kaufsignal!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrSeagen, after $42M victory, suffers loss in ADC patent feud with Daiichi
FrTwo deaths after Novartis' Zolgensma put gene therapy's liver safety in the spotlight once again
FrPfizer in catch-up mode with Merck shows data that could fetch Prevnar 20 a key approval
FrAstraZeneca's Enhertu breaks more ground, nabbing fast FDA nod in HER2-mutant lung cancer
FrFierce Pharma Asia-Enhertu's historic nod; Hutchmed's trial wins; BeiGene, Novartis' liver cancer readout
DoGSK's rotavirus vaccine temporarily runs short, and 'manufacturing challenges' are to blame
DoEMA warns of shortage of IVF drug Cetrotide because of Merck KGaA manufacturing issue
DoAfter Roe ruling, Bayer enlists lobbyists to fight for contraceptive access
DoAs orders slow to a halt, J&J partner Aspen may have to redirect manufacturing efforts: report
DoBlueprint exec spots key Ayvakit readout, dealmaking plan as 'independent precision therapy company'
DoMarket reaction to Sanofi's upcoming litigation over Zantac is 'overblown,' analysts say
DoModerna CEO touts plan for triple combo respiratory shot in 'three to five years': report
MiNovartis' new rare disease drug Vijoice named as an 'empty vessel poised to be filled'
MiBristol Myers, in close CAR-T race with J&J and Legend, touts Abecma win in earlier myeloma
MiGSK, IQVIA team up on 'Vaccine Track' to spotlight shot trends across the US
MiNew CEO Maselli extends Catalent's expansion blitz with $475M buyout of CDMO Metrics
MiSomething to frown about: Revance slapped with another FDA citation, putting approval hopes for Botox rival in limbo
MiFDA relaxes impurity limit on Merck's blockbuster diabetes med Januvia after testing flags possible carcinogen. Are recalls next?
MiBavarian Nordic's monkeypox vaccine supply quintupled in US thanks to FDA 'dose-sparing' switch
DiNo DIY mole removal. FDA cracks down on Amazon, other companies for selling unapproved products
DiIn warranty program, Pfizer will refund up to $50K for patients who discontinue use of rare disease drug
DiNovartis, BeiGene's PD-1 hits goal in first-line liver cancer. Should Roche worry about Tecentriq?
DiAfter FDA snub, Hutchmed touts promising data for two other oncology meds
DiAmid $1B downsizing, Biogen lists Boston-area office space for sublease
DiBARDA backs Opiant to help get nasal opioid overdose drug over the FDA line